rs137853042
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004646.4(NPHS1):c.3325C>T(p.Arg1109Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000632 in 1,613,818 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_004646.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NPHS1 | NM_004646.4 | c.3325C>T | p.Arg1109Ter | stop_gained | 26/29 | ENST00000378910.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NPHS1 | ENST00000378910.10 | c.3325C>T | p.Arg1109Ter | stop_gained | 26/29 | 1 | NM_004646.4 | P2 | |
NPHS1 | ENST00000353632.6 | c.3205C>T | p.Arg1069Ter | stop_gained | 25/28 | 5 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151978Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000155 AC: 39AN: 251456Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135902
GnomAD4 exome AF: 0.0000677 AC: 99AN: 1461840Hom.: 0 Cov.: 34 AF XY: 0.0000674 AC XY: 49AN XY: 727224
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151978Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74220
ClinVar
Submissions by phenotype
Finnish congenital nephrotic syndrome Pathogenic:9
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 23, 2021 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 15, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 11, 2019 | NM_004646.3(NPHS1):c.3325C>T(R1109*, aka Fin minor) is classified as pathogenic in the context of nephrotic syndrome, NPHS1-related. Sources cited for classification include the following: PMID 20507940, 11854170, 10972661, 20172850, 9915943 and 9660941. Classification of NM_004646.3(NPHS1):c.3325C>T(R1109*, aka Fin minor) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 16, 2024 | The p.Arg1109X variant in NPHS1 has been reported in the homozygous or compound heterozygous state in >10 individuals with nephrotic syndrome (Kestilä 1998 PMID: 9660941, Sinha 2020 PMID: 31655822, Zhu 2022 PMID: 35755072). It has also been identified in 0.10% (64/63990) of Finnish chromosomes by gnomAD (http://gnomad.broadinstitute.org). However, this frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID 6867). This nonsense variant leads to a premature termination codon at position 1109, which is predicted to lead to a truncated or absent protein. Loss of function of the NPHS1 gene is an established disease mechanism in autosomal recessive nephrotic syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive nephrotic syndrome. ACMG/AMP Criteria applied: PM3_Very strong, PVS1. - |
Pathogenic, criteria provided, single submitter | clinical testing | Vasylyeva lab, Texas Tech University Health Sciences Center | Nov 23, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 31, 2016 | Variant summary: The NPHS1 c.3325C>T (p.Arg1109X) variant, also known as Fin-minor, results in a premature termination codon, predicted to cause a truncated or absent NPHS1 protein due to nonsense mediated decay (NMD), which are commonly known mechanisms for disease. This variant was found in 25/121560 control chromosomes at a frequency of 0.0002057, which is lower than the estimated maximal expected allele frequency of a pathogenic NPHS1 variant (0.0033541). This variant is a known pathogenic variant with consistent genotype-phenotype data and the variant is mainly found in Finnish population (Kestila_1998, Lenkkeri_1999, Patrakka_2000, Koziell_2002, Machuca_2010, Sadowski_2015). In vitro functional assay shows that this variant abrogates the binding of the protein to podocin (Huber_2003). Taken together, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | research | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 25, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 06, 2024 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2024 | This sequence change creates a premature translational stop signal (p.Arg1109*) in the NPHS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NPHS1 are known to be pathogenic (PMID: 11317351, 11854170, 12039988). This variant is present in population databases (rs137853042, gnomAD 0.06%). This premature translational stop signal has been observed in individual(s) with congenital nephrotic syndrome (PMID: 31655822). ClinVar contains an entry for this variant (Variation ID: 6867). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at